Francesco Don Innocenti

Dr. Francesco Don Innocenti

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Psychological Methods
Verified
Journal Article
Closed access
FIFrancesco Don Innocenti
Francesco Don Innocenti
FTFrans E. S. Tan
Frans E. S. Tan
MCMath Candel
Math Candel
GBGerard J. P. van Breukelen
Gerard J. P. van Breukelen
To prevent mistakes in psychological assessment, the precision of test norms is important. This can be achieved by drawing a large normative sample and using regression-based norming. Based on that norming method, a procedure for sample size planning to make inference on Z-scores and percentile rank scores is proposed. Sampling variance formulas for these norm statistics are derived and used to obtain the optimal design, that is, the optimal predictor distribution, for the normative sample, thereby maximizing precision of estimation. This is done under five regression models with a quantitative and a categorical predictor, differing in whether they allow for interaction and nonlinearity. Efficient robust designs are given in case of uncertainty about the regression model. Furthermore, formulas are provided to compute the normative sample size such that individuals' positions relative to the derived norms can be assessed with prespecified power and precision. (PsycInfo Database Record (c) 2023 APA, all rights reserved).

24 November 2025 in Hepatology Communications
Verified
Journal Article
Open access
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Don Innocenti
Francesco Don Innocenti
OKOzgur Muhammet Koc
Ozgur Muhammet Koc
AEAyşe Eylül
Ayşe Eylül
VYVolkan D. Yumuk
Volkan D. Yumuk
GKGer H. Koek
Ger H. Koek
Background: Dietary interventions are key for managing metabolic dysfunction–associated steatotic liver disease (MASLD), yet optimal diets and the role of PNPLA3 in modulating response to diet remain unclear. We evaluated the efficacy of a Mediterranean diet (MD) versus a low-fat diet (LFD) on hepatic fat and fibrosis, assessing interactions with PNPLA3 genotype. Methods: Two hundred fifty adults with MASLD with BMI ≥25 kg/m 2 were randomized to a 12-week moderately hypocaloric MD or LFD intervention. Individuals with excess alcohol intake and other etiologies of steatosis were excluded. Subjects were genotyped for PNLPA3 single-nucleotide polymorphism. Anthropometric measures, blood tests, and liver assessments [controlled attenuation parameter (CAP) and liver stiffness measurement (LSM)] were conducted at baseline and follow-up. Essential food items were provided, and adherence was tracked using validated questionnaires. The primary outcome was CAP, analyzed using linear mixed models adjusted for age and metabolic syndrome. Results: Both diets significantly reduced CAP, LSM, and body weight at follow-up, with no significant differences between groups. The mean difference between MD and LFD was −0.13 dB/m for CAP ( p =0.976, 95% CI: −8.54, 8.28), −0.19 kPa for LSM ( p =0.355, 95% CI: −0.58, 0.21), and 3.01 kg for weight ( p =0.159, 95% CI: −7.21, 1.19). PNPLA3 genotype did not significantly interact with diet for CAP, LSM, or weight ( p =0.286, p =0.464, p =0.622, respectively). Conclusions: Weight reduction achieved by MD and LFD is similarly efficient in steatosis and fibrosis reduction, while PNPLA3 genotype does not affect the response to diet. Further studies investigating the impact of diet and nutrigenetics on liver-related outcomes are warranted.

17 September 2020 in Statistical Methods in Medical Research
Verified
Journal Article
Open access
PDF file
FIFrancesco Don Innocenti
Francesco Don Innocenti
MCMath Candel
Math Candel
FTFrans Es Tan
Frans Es Tan
GBGerard Jp van Breukelen
Gerard Jp van Breukelen
To estimate the mean of a quantitative variable in a hierarchical population, it is logistically convenient to sample in two stages (two-stage sampling), i.e. selecting first clusters, and then individuals from the sampled clusters. Allowing cluster size to vary in the population and to be related to the mean of the outcome variable of interest (informative cluster size), the following competing sampling designs are considered: sampling clusters with probability proportional to cluster size, and then the same number of individuals per cluster; drawing clusters with equal probability, and then the same percentage of individuals per cluster; and selecting clusters with equal probability, and then the same number of individuals per cluster. For each design, optimal sample sizes are derived under a budget constraint. The three optimal two-stage sampling designs are compared, in terms of efficiency, with each other and with simple random sampling of individuals. Sampling clusters with probability proportional to size is recommended. To overcome the dependency of the optimal design on unknown nuisance parameters, maximin designs are derived. The results are illustrated, assuming probability proportional to size sampling of clusters, with the planning of a hypothetical survey to compare adolescent alcohol consumption between France and Italy.

24 December 2025 in Annals of Hepatology
Verified
Journal Article
Open access
LHLeen Heyens
Leen Heyens
DMDemi P.A. van Malde
Demi P.A. van Malde
GUGediz Dogay Us
Gediz Dogay Us
FIFrancesco Don Innocenti
Francesco Don Innocenti
MSMathieu Struyve
Mathieu Struyve
IAI.N. Akpinar
I.N. Akpinar
The screening accuracy of non-invasive fibrosis tests like FIB-4 in metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Using standard cut-offs, this study evaluated FIB-4's agreement with vibration-controlled transient elastography (VCTE) and identified and validated new thresholds. A prospective cohort study (2019-2024) in Belgian and Dutch primary care used VCTE by FibroScan® (Echosens, France) as a proxy for the fibrosis stage. The FIB-4 index was derived from electronic patient data and study blood samples. Agreement between VCTE and FIB-4 was analysed using weighted Cohen's kappa. New fibrosis cut-offs (≥F2; ≥8 kPa) for ≤65 and >65 years were determined via Youden's Index and validated in a Turkish primary care cohort and a Belgian secondary care T2DM cohort. Among 563 participants (median age 62 years, 47.1 % male, 14.2 % with T2DM, median BMI 28.2 kg/m²), FIB-4 showed poor agreement with VCTE (κ = 0.138, 95 % CI: 0.069-0.207). Suggested new cut-offs of 1.29 (≤65 years) and 1.72 (>65 years) were proposed. The 1.29 cut-off performed similarly to the existing 1.3 in validation cohorts. In the Türkiye and T2DM cohorts, the 1.72 cut-off improved sensitivity over 2.0 but had lower specificity. The FIB-4 index showed poor agreement with VCTE and low sensitivity, making it an unreliable standalone diagnostic tool for liver fibrosis in people with MASLD in both primary and secondary care. Alternative non-invasive tests or improved cut-off values are needed for accurate fibrosis detection in clinical practice.

21 December 2018 in Statistics in Medicine
Verified
Journal Article
Open access
PDF file
FIFrancesco Don Innocenti
Francesco Don Innocenti
MCMath Candel
Math Candel
FTFrans E.S. Tan
Frans E.S. Tan
GBGerard J.P. van Breukelen
Gerard J.P. van Breukelen
In multilevel populations, there are two types of population means of an outcome variable ie, the average of all individual outcomes ignoring cluster membership and the average of cluster‐specific means. To estimate the first mean, individuals can be sampled directly with simple random sampling or with two‐stage sampling (TSS), that is, sampling clusters first, and then individuals within the sampled clusters. When cluster size varies in the population, three TSS schemes can be considered, ie, sampling clusters with probability proportional to cluster size and then sampling the same number of individuals per cluster; sampling clusters with equal probability and then sampling the same percentage of individuals per cluster; and sampling clusters with equal probability and then sampling the same number of individuals per cluster. Unbiased estimation of the average of all individual outcomes is discussed under each sampling scheme assuming cluster size to be informative. Furthermore, the three TSS schemes are compared in terms of efficiency with each other and with simple random sampling under the constraint of a fixed total sample size. The relative efficiency of the sampling schemes is shown to vary across different cluster size distributions. However, sampling clusters with probability proportional to size is the most efficient TSS scheme for many cluster size distributions. Model‐based and design‐based inference are compared and are shown to give similar results. The results are applied to the distribution of high school size in Italy and the distribution of patient list size for general practices in England.

19 November 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
LHLeen Heyens
Leen Heyens
FIFrancesco Don Innocenti
Francesco Don Innocenti
CSChristophe Van Steenkiste
Christophe Van Steenkiste
MSMathieu Struyve
Mathieu Struyve
SFSven M Francque
Sven M Francque
OGon behalf of the MASLD Research Group
on behalf of the MASLD Research Group
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely intertwined with glucose metabolism status (GMS). Bi-national comparative epidemiological data are lacking; therefore, this study aimed to provide new insights into MASLD and fibrosis prevalence and risk factors in Belgium, while comparing data from The Netherlands to uncover cross-country differences. Materials and Methods: A prospective cohort study (2019–2024) in Belgian primary and secondary care was compared with the Dutch Maastricht Study. Liver fat was measured using CAP (FibroScan®), and anthropometric, clinical, and biochemical data were collected. Associations with CAP were analysed using multivariable linear regression, including sex, age, BMI, MetS, high SBP, CVD history, and country. Results: A total of 2436 individuals (Belgium and The Netherlands) were screened, of which 1928 were eligible: MASLD with normal GMS (38.3%), prediabetes (19.2%), and type 2 diabetes mellitus (T2DM; 42.5%). Belgian participants with T2DM had higher BMI and prevalence of MASLD. CAP values were significantly associated with female sex (−7.5 dB/m, 95%CI (−11.834; −3.056), p < 0.001), BMI (5.184 dB/m, 95%CI (4.627; 5.741), p < 0.001), and MetS (13.7 dB/m, 95%CI (8.456; 18.994), p < 0.001). Country-specific interactions showed differing effects of high SBP and CVD on CAP between Belgium and The Netherlands, with only the inverse association of CVD history (−10.756, 95%CI (−17.485; −4.027), p = 0.002) with CAP in The Netherlands being significant. Conclusions: MASLD and fibrosis are common in people with prediabetes and T2DM, underscoring the need for early detection and management. Obesity and metabolic risk were key factors, while a history of CVD appeared protective in the Dutch cohort but not in the Belgian one.